Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis - Top-Institutions - MDSpire

Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis

  • By

  • Liwei Sun

  • Jinduo Li

  • Yuan Lv

  • Lin Li

  • Xiaomin Liu

  • September 30, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-oncology
    • Thoracic Oncology
    • Molecular Pathology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Thoracic Oncology
    • Neuro-oncology
    • Cancer Genomics

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neuro-oncology
    • Thoracic Oncology
    • Molecular Oncology

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Neuro-oncology
    • Thoracic Oncology
    • Genomic Medicine

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Neuro-oncology
    • Thoracic Oncology
    • Cancer Genomics

Original Source(s)

Unravelling genomic differences in cerebrospinal fluid: patients with lung cancer with combined brain parenchymal and meningeal metastasis versus exclusive meningeal metastasis

  • by Liwei Sun, Jinduo Li, Yuan Lv, Lin Li, Xiaomin Liu

  • September 30, 2025

Related Content

Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices

Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells